News
Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume ...
Veracyte's Q2 results show strong revenue growth, margin expansion, and a robust cash position, reinforcing my long-term ...
I agree with you that he should have asked you first, but he didn’t and you tacitly forgave that by having sex. If the ...
Procept BioRobotics Corporation targets a $20B BPH market with innovative robotics. Explore growth potential, revenue trends, ...
Q2 2025 Earnings Call Transcript August 14, 2025 Profound Medical Corp. misses on earnings expectations. Reported EPS is ...
1d
The Punch on MSNSick and stranded: Presidential order fails to curb soaring drug prices
Despite President Bola Tinubu’s executive order in June 2024 aimed at reducing drug costs by abolishing tariffs, excise ...
Second quarter 2025 net loss was approximately $15.7 million, or $0.52 per common share, compared to approximately $6.9 million, or $0.28 per common share, in the three months ended June 30, 2024. As ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable ...
It affects up to 40 per cent of the population, yet the need to repeatedly use the toilet at night can be difficult to ...
Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good afternoon, and welcome to the PROCEPT BioRobotics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, ...
These 10 stocks could mint the next wave of millionaires › Procept BioRobotics (NASDAQ:PRCT), a medical technology company specializing in robotic surgical systems for benign prostatic hyperplasia ...
Discover the latest non-invasive Alzheimer’s detection breakthroughs, from AI and heart rate tracking to digital twins and sensor tests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results